April 30, 2004
German drugmaker Schering AG on Friday unveiled upbeat early results of phrase III tests in its "Beyond" trial, one of the biggest multiple sclerosis (MS) studies ever.
Initial results from the trial showed that a higher dose of its key multiple sclerosis drug Betaferon may have a positive effect on relapsing-remitting MS patients, compared to the standard dose.
"These first data support our conviction that a higher dose of Betaferon could exert even greater therapeutic benefits for MS patients than known from any other drug on the market," Joachim-Friedrich Kapp, head of specialised therapeutics at Schering, said in a statement.
The Beyond program is a continuing multinational, phase III trial and
involves more than 2,000 patients. The data, the first efficacy outcomes
from the study, were presented at a conference in San Francisco.
Copyright © 2004, Reuters